The latest report from EP Vantage reviews the performance of the medtech industry in the first half of 2014 and reveals that after a shocking year in which mergers, funding and FDA approvals all slipped badly, the sector is finally seeing improvements across the board.
Key findings include::
The combined value of acquisitions reached $27.2 billion during the first half of the year, surpassing the full-year total for 2013 with an increase of more than 40 percent
Second quarter venture capital deals rose 33 percent over the first quarter, exceeding the billion-dollar mark for the first time since the second quarter of 2013
The FDA awarded 17 first-time PMAs in the first half of 2014, nearly double the nine awarded in the first half of 2013. Moreover, the devices have been assessed almost twice as fast as the same period last year
To download this report, please confirm your details on the form opposite.